Schizophrenia Research Forum - A Catalyst for Creative Thinking


Liu YL, Fann CS, Liu CM, Chang CC, Yang WC, Hung SI, Yu SL, Hwang TJ, Hsieh MH, Liu CC, Tsuang MM, Wu JY, Jou YS, Faraone SV, Tsuang MT, Chen WJ, Hwu HG. More evidence supports the association of PPP3CC with schizophrenia. Mol Psychiatry. 2007 Mar 6 ; Pubmed Abstract

Comments on Related News


Related News: Genetics and Schizophrenia—Calcineurin Connection Grows

Comment by:  Mary Reid
Submitted 26 February 2007
Posted 27 February 2007

Tom Fagan mentions that calcineurin regulates phosphorylations elicited by both glutamatergic and dopaminergic signaling. The activity of D-amino acid oxidase is increased in schizophrenia, and this also affects signaling through both these pathways. Is there any clinical benefit with the use of sodium benzoate which inhibits DAO activity?

He also mentions that EGR3 can be regulated by the activity of neuregulin. Interestingly, Roberts et al. suggest that BDNF, which is decreased in first-episode psychosis (Buckley et al., 2007), induces synthesis of EGR3 to regulate activity of GABRA4. Ma and colleagues (Ma et al., 2005) conclude that GABRA4 is involved in the etiology of autism and it has also has been implicated in nicotine dependence (Saccone et al., 2007).

Glorioso and colleagues (Glorioso et al., 2006) report changes in genes encoding early-immediate genes such as EGR1 and EGR2 and RGS4 which is involved in cellular signaling and has been implicated in schizophrenia following BDNF gene ablation. Several studies report that zinc increases BDNF expression. Does this give support to the zinc deficiency theory of schizophrenia?

View all comments by Mary Reid